How, in the setting of lung cancer, specifically should oncologists optimally deploy specific NGS technologies, especially those that use hybrid capture to identify molecular drivers of NSCLC in the clinic?

How, in the setting of lung cancer, specifically should oncologists optimally deploy specific NGS technologies, especially those that use hybrid capture to identify molecular drivers of NSCLC in the clinic?

How, in the setting of lung cancer, specifically should oncologists optimally deploy specific NGS technologies, especially those that use hybrid capture to identify molecular drivers of NSCLC in the clinic?